

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2004/0259247 A1	12-23-2004	Tuschl <i>et al.</i>	All
	U2	US-2005/0106598 A1	05-19-2005	Manoharan <i>et al.</i>	All
	U3	US-6,391,318	05-21-2002	Illum <i>et al.</i>	All
	U4	US-7,297,786	11-20-2007	McCray <i>et al.</i>	All
	U5				
	U6				
	U7				
	U8				
	U9				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2**Complete if Known**

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	CHHABRA, A. <i>et al.</i> "Silencing of Endogenous IL-10 in Human Dendritic Cells Leads to the Generation of an Improved CTL Response Against Human Melanoma Associated Antigenic Epitope, MART-1" <i>Clin Immunol.</i> , March 2008, 126(3):251-259.	
	R2	HEALE, B.S.E. <i>et al.</i> "siRNA target site secondary structure predictions using local stable substructures" <i>Nucleic Acids Research</i> , 2005, 33(3):e30, pp. 1-10.	
	R3	HILL, J.A. <i>et al.</i> "Immune Modulation by Silencing IL-12 Production in Dendritic Cells Using Small Interfering RNA" <i>The Journal of Immunology</i> , 2003, 171:691-696.	
	R4	KRETSCHMER-KAZEMI, R. <i>et al.</i> "The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides" <i>Nucleic Acids Research</i> , 2003, 31(15):4417-4424.	
	R5	LI, M. <i>et al.</i> "Immune Modulation and Tolerance Induction by RelB-Silenced Dendritic Cells through RNA Interference" <i>The Journal of Immunology</i> , 2007, 178:5480-5487.	
	R6	NAIR, M.P.N. <i>et al.</i> "RNAi-directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy" <i>The AAPS Journal</i> , 2005, 7(3):E572-E578.	
	R7	NAWTAISONG, P. <i>et al.</i> "Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome" <i>Virology Journal</i> , 2009, 6:73, pp. 1-17.	
	R8	QIAN, H. <i>et al.</i> "Silencing CD40 in Dendritic Cells by siRNA" <i>12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Canada, July 18-23, 2004</i> , 2004, pp. 339-348.	
	R9	SHAO, Y. <i>et al.</i> "Effect of target secondary structure on RNAi efficiency" <i>RNA</i> , 2007, 13:1631-1640.	
	R10	WESTERHOUT, E.M. <i>et al.</i> "A systematic analysis of the effect of target RNA structure on RNA interference" <i>Nucleic Acids Research</i> , 2007, 35(13):4322-4330.	
	R11	YOSHINARI, K. <i>et al.</i> "Effects on RNAi of the tight structure, sequence and position of the targeted region" <i>Nucleic Acids Research</i> , 2004, 32(2):691-699.	
	R12		
	R13		

Examiner Signature	/Richard Schnizer/	Date Considered	10/25/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.